Stock Price Movement and Market Context
On 27 Jan 2026, Krebs Biochemicals & Industries Ltd's share price fell sharply, registering a day change of -5.51%, underperforming its sector by over 100%. The stock is now trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. This decline has brought the stock to its lowest price point in the past 52 weeks, a level last seen over a year ago.
The broader market backdrop has also been unfavourable. The Sensex opened 100.91 points lower and is currently trading at 81,280.40, down 0.32%. The index has experienced a three-week consecutive fall, losing 2.75% over this period. Notably, other indices such as NIFTY MEDIA and NIFTY REALTY also hit new 52-week lows on the same day, indicating sector-wide pressures.
Financial Performance and Fundamental Assessment
Krebs Biochemicals & Industries Ltd's financial metrics reveal several areas of concern. The company has reported negative results for four consecutive quarters, with the latest nine-month Profit After Tax (PAT) standing at a loss of ₹19.73 crores, reflecting a decline of 58.24%. Net sales for the latest six months have also contracted sharply by 62.52%, amounting to ₹9.65 crores. These figures highlight a significant downturn in the company’s revenue generation and profitability.
The company’s long-term growth trajectory has been weak, with net sales declining at an annual rate of 11.65% over the past five years, while operating profit has remained stagnant at 0%. Additionally, the company carries a negative book value, indicating weak long-term fundamental strength. Despite being classified as a high-debt company, the average Debt to Equity ratio stands at zero, which may reflect accounting nuances or restructuring but does not alleviate concerns over financial health.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Valuation and Trading Characteristics
The stock’s valuation metrics further illustrate its current risk profile. It is trading at levels considered risky relative to its historical averages. Over the past year, the stock has delivered a return of -38.09%, significantly underperforming the Sensex, which posted a positive return of 7.81% over the same period. Profitability has also deteriorated, with profits falling by 26.2% in the last year.
Liquidity and turnover ratios add to the picture of subdued market interest. The Debtors Turnover Ratio for the half-year is at a low 19.44 times, indicating slower collection cycles. The stock has also experienced erratic trading patterns, having not traded on one day out of the last 20, which may reflect lower liquidity or investor caution.
Long-Term and Sectoral Performance
In addition to recent underperformance, Krebs Biochemicals & Industries Ltd has lagged behind the broader BSE500 index over multiple time frames, including the last three years, one year, and three months. This sustained underperformance highlights challenges in maintaining competitive positioning within the Pharmaceuticals & Biotechnology sector.
The company’s Mojo Score currently stands at 9.0, with a Mojo Grade of Strong Sell, an upgrade from the previous Sell grade on 6 Feb 2025. The Market Cap Grade is rated at 4, reflecting its micro-cap status and associated risks.
Krebs Biochemicals & Industries Ltd or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Shareholding and Corporate Structure
The majority shareholding of Krebs Biochemicals & Industries Ltd remains with the promoters, indicating concentrated ownership. This structure can influence strategic decisions and market perceptions, particularly in times of financial stress or price volatility.
Despite the challenges faced, the stock’s 52-week high was ₹113.90, underscoring the extent of the decline to current levels. The contrast between the peak and the recent low highlights the volatility and the pressures the company has encountered over the past year.
Summary of Key Metrics
To summarise, Krebs Biochemicals & Industries Ltd’s key financial and market indicators as of January 2026 are:
- 52-week low reached, with significant underperformance relative to sector and benchmark indices
- Negative PAT of ₹19.73 crores over nine months, down 58.24%
- Net sales of ₹9.65 crores in the latest six months, down 62.52%
- Negative book value and weak long-term fundamentals
- Mojo Score of 9.0 and Strong Sell grade
- Trading below all major moving averages
- Debt to Equity ratio averaging zero despite classification as a high-debt company
- Debtors Turnover Ratio at 19.44 times, indicating slower receivables collection
The stock’s current position at a 52-week low reflects a combination of subdued financial results, valuation concerns, and broader market pressures within the Pharmaceuticals & Biotechnology sector. These factors collectively contribute to the stock’s challenging performance over the past year and beyond.
Unlock special upgrade rates for a limited period. Start Saving Now →
